Author Archives: Lu Rahman

#Metabolomics #Pharmaceuticals #Research & development

Boosting pharmaceutical research with microbiome data

Microbiome-based evidence is set to drive understanding of how drugs interact with human ‘host’ environments, helping devise more targeted treatments and create business opportunities, reports Anthony Finbow, CEO of Eagle Genomics. The microbiology of the drug recipient impacts their immune response, allergic responses and more. Increasingly, life sciences R&D is… Read More

#Editor's Choice #Exclusive Content #News #Trends & Analysis

#Bioinformatics #Informatics #Pharmaceutical #Phosphoproteomic

Is this start-up a game changer for drug discovery?  

Jane Theaker, Kinomica explains why she was so impressed with the preclinical datasets predicting for drug response that the company could produce, she decided to join as CEO. Kinomica is a spin out offering phosphoproteomic analyses to the pharmaceutical industry. Theaker has R&D expertise in novel diagnostic technologies. Her experience… Read More

#News #Start-up Zone

#Clinical trials #Covid-19 #Drug development

ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial

ICON, provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, has announced it provided clinical trial services to the Pfizer and BioNTech investigational COVID-19 vaccine programme. Pfizer and BioNTech announced positive efficacy results from a… Read More

#Covid-19 #News

#Research #Research & development

ELRIG announces Early Career Professional Impact award

ELRIG recognises and celebrates Early Career Professionals (ECPs) that make a clear impact on the wider scientific community. This may be achieved in a variety of ways: Through delivery of impactful science, contributing to early, pre-clinical drug discovery by science or technology development work via leadership or facilitation of collaborations in… Read More

#News

#Biologics #Cell therapy #CRISPR #Gene therapy #Immuno-oncology

Cognate BioServices announces major US and Europe expansion

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new… Read More

#News

#Drug discovery

Drug discovery collaboration in neurological diseases

Servier, a global pharmaceutical group and X-Chem, a privately held drug discovery company have teamed up to identify and develop novel small molecules for the treatment of neurological disorders. Under the terms of the multi-target agreement, X-Chem will use its DNA-Encoded library (DEL) platform to identify novel small molecule leads… Read More

#News

Automation expertise with Festo at SLAS2021 Digital

The healthcare sector worldwide is facing ever greater challenges – challenges that could also be addressed by industrial automation. With this in mind, Festo’s Life Sciences division offers forward-looking answers as well as innovative solutions for laboratory automation, biotech, pharmaceuticals, in-vitro diagnostics, and medical technology. Festo says it supports systems… Read More

#News

#R&D

LifeNet Health launches innovative service for researchers

LifeNet Health has expanded its LifeSciences division offering human cell- and tissue-based research solutions through a new website, LNHLifeSciences.org. LifeNet Health says it has recovery, handling and preservation protocols — assuring tissue integrity and quality are sustained throughout the entire process. The organisation offers expertise with the recovery of an… Read More

#News

#Events

SLAS 2021 European Sample Management Hybrid Symposium registration open

Registration is now open for April’s SLAS 2021 European Sample Management Hybrid Symposium in Berlin, Germany (26-27 April). To abide by current location regulations, SLAS plans to conduct this symposium as a hybrid event, meaning both live and online-only registration and attendance will be available. Join the event in-person or… Read More

#News

#Drug discovery

CN Bio’s PhysioMimix technology receives FDA recognition

CN Bio, developer of single and multi organ-on-chip microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, has published co-authored research with the US Food and Drug Administration (FDA)1.The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using… Read More

#Editor's Choice #News

#Drug discovery #Exhibition

SLAS2021 Digital: expertise and innovation showcase

SLAS2021 Digital will take place on 25-27 January. This year’s event promises expertise and innovation from the life sciences discovery and technology sectors. The event welcomes scientists, engineers, academics, graduate students, post-doctorates and business leaders from academia, government and industry who want to immerse themselves in the latest innovation for discovery,… Read More

#Editor's Choice #News

#Drug discovery

Five reasons why Australia holds opportunity for drug discovery projects

Colin La Galia, Epichem CEO, explains why Australia is one of international science’s ‘best kept secrets’. In an uncertain domestic environment, many drug discovery companies are looking to find safe, reliable locations to continue their important work in chemical and pharmaceutical development. There are several compelling reasons companies should consider… Read More

#News

#Antibodies

OXGENE’s SLIM platform for discovery of antibodies against membrane proteins

OXGENE has announced the introduction of its self-labelling integral membrane (SLIM) protein discovery system. The novel method allows for the identification of antibodies against membrane proteins in their native configuration in mammalian cells, which could catalyse the discovery of new candidates for antibody-based therapies. In SLIM display, a target membrane… Read More

#News